scholarly journals Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer

2013 ◽  
Vol 3 ◽  
Author(s):  
Panagiotis A. Konstantinopoulos ◽  
Ursula A. Matulonis
Keyword(s):  
Ovarian Cancer ◽  
Drug Development ◽  
Epithelial Ovarian Cancer ◽  
Current Status ◽  
Development Models ◽  
Preclinical Drug Development

scholarly journals Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction

2021 ◽  
Vol 11 ◽  
Author(s):  
Ying-Cheng Chiang ◽  
Po-Han Lin ◽  
Wen-Fang Cheng
Keyword(s):  
Ovarian Cancer ◽  
Homologous Recombination ◽  
Epithelial Ovarian Cancer ◽  
Recurrent Disease ◽  
Synthetic Lethality ◽  
Parp Inhibitor ◽  
Current Status ◽  
Homologous Recombination Deficiency ◽  
Platinum Based Chemotherapy ◽  
Future Direction

Epithelial ovarian cancer (EOC) patients are generally diagnosed at an advanced stage, usually relapse after initial treatments, which include debulking surgery and adjuvant platinum-based chemotherapy, and eventually have poor 5-year survival of less than 50%. In recent years, promising survival benefits from maintenance therapy with poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) has changed the management of EOC in newly diagnosed and recurrent disease. Identification of BRCA mutations and/or homologous recombination deficiency (HRD) is critical for selecting patients for PARPi treatment. However, the currently available HRD assays are not perfect predictors of the clinical response to PARPis in EOC patients. In this review, we introduce the concept of synthetic lethality, the rationale of using PARPi when HRD is present in tumor cells, the clinical trials of PARPi incorporating the HRD assays for EOC, the current HRD assays, and other HRD assays in development.

Impact of extended cycles of chemotherapy on survival outcome in recurrent epithelial ovarian cancer

2020 ◽  
Vol 159 ◽  
pp. 346-347
Author(s):  
W.Y. Hwang ◽  
S.I. Kim ◽  
M. Lee ◽  
K. Kim ◽  
J.H. No ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Survival Outcome

Die personalisierte Therapie beim Ovarialkarzinom

2018 ◽  
Vol 39 (03) ◽  
pp. 180-186
Author(s):  
Ann-K. Langner ◽  
Nina Pauly ◽  
Beyhan Ataseven ◽  
Andreas du Bois
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Personalisierte Medizin ◽  
Personalisierte Therapie

Die Behandlung des epithelialen Ovarial-, Tuben- und Peritonealkarzinoms (epithelial ovarian cancer; EOC) fußt auf 3 Säulen, die in unterschiedlichem Maße individualisierte bzw. personalisierte Medizin inkludieren:

Sign in / Sign up

Export Citation Format

Share Document